EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders

Marco C Miotto iD, Estefania Luna-Figueroa, Carl Tchagou, Laith Bahlouli, Steven Reiken iD, Haikel Dridi, Yang Liu iD, Gunnar Weninger iD, Andrew R Marks iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2422082122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Marco C Miotto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Allopurinol, Xanthine, Muscle Weakness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), NINDS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ryanodine receptors (RyRs) are intracellular Ca 2+ channels essential for muscle contraction. Caffeine, a xanthine derivative, has been known for decades to increase muscle contraction and enhance activation of RyRs by increasing the sensitivity to Ca 2+ . We previously showed that xanthine, the only physiologically relevant xanthine derivative, also binds to and activates RyR2. Most xanthine derivatives and analogs are safe and widely prescribed, with the most popular being the xanthine oxidoreductase inhibitor allopurinol (~15M yearly prescriptions in USA). We propose that xanthine derivatives and analogs that enhance RyRs activity could be used for lead optimization and eventually for the treatment of the diseases that exhibit decreased muscle contraction and reduced RyRs activity, such as RyR1-related diseases, sarcopenia, and heart failure. Here, we show by cryo-EM that xanthine derivatives, analogs, and other related compounds bind to the xanthine/caffeine binding site and activate RyR1, and identify 4-oxopyrimidine as the minimal motif necessary for such interaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelAllopurinolXanthineMuscle WeaknessXanthinesHumansCaffeineAnimalsBinding SitesCalciumHeart Failure

Stichwörter der Autor:innen

allopurinolcalcium sensitizingcardiac and muscle weaknessryanodine receptorxanthine derivatives

Substanzen

Ryanodine Receptor Calcium Release ChannelAllopurinolXanthineCaffeineXanthinesCalcium

Autor:innen und Institutionen

  • Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
  • Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Medical Center, New York, NY 10032.

ORCID-Profile: Marco C Miotto, Steven Reiken, Yang Liu, Gunnar Weninger, Andrew R Marks

Förderung

  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • NINDS NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Miotto, M. C., Luna-Figueroa, E., Tchagou, C., Bahlouli, L., Reiken, S., Dridi, H., Liu, Y., Weninger, G., & Marks, A. R. (2025). Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2422082122

Vancouver

Miotto MC, Luna-Figueroa E, Tchagou C, Bahlouli L, Reiken S, Dridi H, et al. Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2422082122

BibTeX
@article{Miotto2025,
  author = {Miotto, Marco C and Luna-Figueroa, Estefania and Tchagou, Carl and Bahlouli, Laith and Reiken, Steven and Dridi, Haikel and Liu, Yang and Weninger, Gunnar and Marks, Andrew R},
  title = {Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2422082122}
}
Kostenlos starten →